Price$18.02+0.09 (+0.50%)
01:30 PM07:45 PM
News · 26 weeks53+175%
2026-01-182026-07-12
Mix3390d
- SEC Filings15(45%)
- Other7(21%)
- Insider7(21%)
- Earnings2(6%)
- Offering1(3%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Morris Arlene4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERSEC Form 4 filed by Director Kiselak Tomas4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERSEC Form 4 filed by Director Gheuens Sarah4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERSEC Form 4 filed by Director Moses Jennifer K.4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERSEC Form 4 filed by Director Ajer Jeffrey Robert4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- INSIDERSEC Form 4 filed by Director Cain Christopher W.4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- FDAFDA Approval for LUMVOA issued to VIRIDIAN THERAPEUTICS INCSubmission status for VIRIDIAN THERAPEUTICS INC's drug LUMVOA (ORIG-1) with active ingredient VELIGROTUG-VVZE has changed to 'Approval' on 06/26/2026. Application Category: BLA, Application Number: 761530, Application Classification:
- PR4 Sizzling Biotech and Healthcare Companies Reporting Strategic MilestonesDENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization. Universe Pharmaceuticals (NASDAQ:UPC) announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.7
- ANALYSTViridian Therapeutics upgraded by Wells Fargo with a new price targetWells Fargo upgraded Viridian Therapeutics from Equal Weight to Overweight and set a new price target of $31.00
- SECViridian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- PRViridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease- First approved treatment for thyroid eye disease (TED) with labeling that includes data for both active and chronic TED - - In two pivotal phase 3 clinical trials, Lumvoa treatment showed rapid, consistent, and durable reductions of the key signs and symptoms of both active and chronic TED - - Lumvoa is the first approved product for TED to show a statistically significant effect in both diplopia response and complete resolution of diplopia in active and chronic disease - - Viridian plans to launch Lumvoa immediately, a pivotal milestone as the company’s first commercial product in TED with subcutaneous elegrobart on track for a biologics license application (BLA) submission in Q1 2
- SECSEC Form 8-K filed by Viridian Therapeutics Inc.8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECSEC Form 8-K filed by Viridian Therapeutics Inc.8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- PRViridian Therapeutics to Participate in Upcoming June Investor ConferencesViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Wednesday, June 3, 2026, at 5:30pm ET in New York, NY Goldman Sachs 47th Annual Global Healthcare Conference: Fireside chat on Tuesday, June 9, 2026, at 4:00pm ET in Miami, FL A live webcast of each presentation can be accessed under "Events and Presentations" on the Investors section of the Viridian website at viridianth
- SECSEC Form 8-K filed by Viridian Therapeutics Inc.8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- INSIDERDirector Fairmount Funds Management Llc bought $19,999,990 worth of shares (1,176,470 units at $17.00) (SEC Form 4)4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Viridian Therapeutics Inc.SCHEDULE 13D/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
- SECViridian Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECSEC Form 424B5 filed by Viridian Therapeutics Inc.424B5 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECSEC Form 424B5 filed by Viridian Therapeutics Inc.424B5 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- SECSEC Form FWP filed by Viridian Therapeutics Inc.FWP - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
- SECSEC Form FWP filed by Viridian Therapeutics Inc.FWP - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
- SECSEC Form 305B2 filed by Viridian Therapeutics Inc.305B2 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
- PRViridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 MillionViridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today announced the pricing of its upsized underwritten public offering of $225.0 million aggregate principal amount of its 1.75% convertible senior notes due 2032 (the "Convertible Notes" and such offering, the "Convertible Notes Offering") and its upsized underwritten public offering of 7,352,942 shares of its common stock at a public offering price of $17.00 per share (such offering, the "Equity Offering"). Viridian estimates that the aggregate net proceeds from the Convertible Notes Offering and th
- SECSEC Form 424B5 filed by Viridian Therapeutics Inc.424B5 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
VRDN FAQ
7 questionsWhat does Viridian Therapeutics Inc. do?
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.Where does VRDN stock trade?
Viridian Therapeutics Inc. (VRDN) is listed on NASDAQ.What sector and industry is VRDN in?
Viridian Therapeutics Inc. operates in the Health Care sector, Medical Specialities industry.When did Viridian Therapeutics Inc. go public?
Viridian Therapeutics Inc. (VRDN) completed its IPO in 2014.What are analysts saying about VRDN?
Viridian Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $3100.00 price target on 2026-06-29. Recent price targets range from $2700.00 to $4700.00.What companies are similar to VRDN?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare VRDN side-by-side with any of them on Quantisnow.How can I track VRDN on Quantisnow?
Quantisnow aggregates Viridian Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VRDN to receive live email and push alerts on every new disclosure.